Conexeu Sciences names Daniel M. Bradbury board chairman, effective Dec. 1
CNXU•Conexeu Sciences appointed Daniel M. Bradbury board chairman, effective December 1, 2026, succeeding Jeff Sharpe, who stepped down as chairman and director.
1. Chairman appointment
Bradbury previously served as Amylin Pharmaceuticals’ president and CEO from March 2007 until its acquisition by Bristol-Myers Squibb in August 2012.




